CPI-0610 carboxylic acid
Code | Size | Price |
---|
TAR-T10879-1mg | 1mg | £493.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T10879-5mg | 5mg | £1,018.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T10879-10mg | 10mg | £1,340.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T10879-25mg | 25mg | £1,958.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T10879-50mg | 50mg | £2,625.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T10879-100mg | 100mg | £3,508.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
CPI-0610 carboxylic acid is a ligand for target protein for PROTAC. It is a potent bromodomain and extra-terminal (BET) protein inhibitor with the potential in the therapy of multiple myeloma.
CAS:
1380089-81-5
Formula:
C20H15ClN2O3
Molecular Weight:
366.8
Pathway:
Chromatin/Epigenetic
Purity:
0.98
SMILES:
Cc1noc2[C@H](CC(O)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12
Target:
Epigenetic Reader Domain
References
1. Albrecht BK, et al. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials. J Med Chem. 2016 Feb 25;59(4):1330-9.